Published in Biokhimiia on November 01, 1995
Evaluation of plasma levels of tumour necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy. Eur Heart J (1997) 1.53
Tissue specificity of enhancer and promoter activities of a HERV-K(HML-2) LTR. Virus Res (2004) 1.41
Destabilase from the medicinal leech is a representative of a novel family of lysozymes. Biochim Biophys Acta (2000) 1.02
Proteins and peptides of the salivary gland secretion of medicinal leeches Hirudo verbana, H. medicinalis, and H. orientalis. Biochemistry (Mosc) (2008) 0.95
Proteinase inhibitors from the medicinal leech Hirudo medicinalis. Biochemistry (Mosc) (2001) 0.94
Aortic valve homografts in the surgical treatment of complex cardiac malformations. J Thorac Cardiovasc Surg (1984) 0.91
[The stimulating effect of destabilase, a component of Hirudo medicinalis salivary gland secretion, on sensory neuron neurite growth in organotypic culture]. Tsitologiia (1999) 0.89
[An effective inhibitor of S-adenosylmethionine decarboxylase]. Bioorg Khim (1983) 0.88
[Thrombolytic action of heparin and a low molecular weight fraction]. Therapie (1985) 0.88
Protein profiling of the medicinal leech salivary gland secretion by proteomic analytical methods. Biochemistry (Mosc) (2004) 0.87
Antibacterial non-glycosidase activity of invertebrate destabilase-lysozyme and of its helical amphipathic peptides. Chemotherapy (2006) 0.87
[Destabilase: an enzyme of medicinal leech salivary gland secretion hydrolyzes the isopeptide bonds in stabilized fibrin]. Biokhimiia (1985) 0.86
What is the effect of acetylsalicylic acid at ultra low dose on the interaction platelets/vessel wall? Thromb Res (1990) 0.85
Thromboembolic complications several days after a single-dose administration of aspirin. Thromb Res (1998) 0.84
Effects of aspirin on embolization in an arterial model of laser-induced thrombus formation. Haemostasis (1993) 0.83
Importance of photo activation of rose bengal for platelet activation in experimental models of photochemically induced thrombosis. Thromb Res (1996) 0.83
Experimental thrombosis model induced by free radicals. Application to aspirin and other different substances. Thromb Res (1995) 0.82
Experimental thrombosis model induced by laser beam. Application of aspirin and an extract of Ginkgo biloba: EGb 761. Thromb Res (1996) 0.82
Combination of two doses of acetyl salicylic acid: experimental study of arterial thrombosis. Thromb Res (1998) 0.81
[Polyfunctionality of destabilase, a lysozyme from a medicinal leech]. Bioorg Khim (2008) 0.81
Multiple forms of medicinal leech destabilase-lysozyme. Biochem Biophys Res Commun (2003) 0.81
Hirudin from leech heads and whole leeches and "pseudo-hirudin" from leech bodies. Thromb Res (1983) 0.81
Effect of the low molecular weight heparin/non steroidal anti-inflammatory drugs association on an experimental thrombosis induced by laser. Thromb Res (1995) 0.80
Recombinant destabilase-lysozyme: synthesis de novo in E. coli and action mechanism of the enzyme expressed in Spodoptera frugiperda. Biochemistry (Mosc) (2004) 0.80
Vascular-platelet and plasma hemostasis regulators from bloodsucking animals. Biochemistry (Mosc) (2002) 0.79
2006 GEP-ISFG collaborative exercise on mtDNA: reflections about interpretation, artefacts, and DNA mixtures. Forensic Sci Int Genet (2007) 0.79
Action of neurotransmitters: acetylcholine, serotonin, and adrenaline in an experimental arterial thrombosis induced by oxygen free radicals. Thromb Res (1997) 0.79
Thrombogenic properties of ultra-low-dose of acetylsalicylic acid in a vessel model of laser-induced thrombus formation. Thromb Res (1994) 0.79
Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res (1983) 0.78
Purification of proteins specifically binding human endogenous retrovirus K long terminal repeat by affinity elution chromatography. J Chromatogr A (2002) 0.78
In vitro platelets/endothelial cells interactions in presence of acetylsalicylic acid at various dosages. Thromb Res (1992) 0.78
Proteomic analysis methods for characterization of proteins from the salivary gland secretions of the medicinal leech during different seasons. Biochemistry (Mosc) (2007) 0.78
Time related neutralization of two doses acetyl salicylic acid. Thromb Res (2000) 0.77
Effects of aprotinin on heparin activities and heparin neutralization with protamine. Thromb Res (1992) 0.77
Destabilase-lysozyme of medicinal leech. Multifunctionality of recombinant protein. Biochemistry (Mosc) (2010) 0.77
Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang (1992) 0.77
[Effect of the salivary gland secretion of medicinal leeches Hirudo medicinalis on the external and internal mechanisms of blood coagulation]. Biull Eksp Biol Med (1984) 0.77
Some hemostatic and hemorheological disorders in auditory and vestibular impairments. Thromb Res (1992) 0.77
[A dimer of fragment D from stabilized fibrin--a substrate for the destabilase enzyme (gamma-glutamyl-epsilon-lysyl-isopeptidase)]. Biokhimiia (1991) 0.77
[Kinetics of L-gamma-Glu-pNA hydrolysis by destabilase, the enzyme from the medicinal leech Hirudo medicinalis]. Biokhimiia (1990) 0.77
[Comparative properties of hirudin from whole leeches and from leech heads and bodies]. Biokhimiia (1980) 0.76
[Purification of hirudin by the method of isoelectric focusing]. Biokhimiia (1976) 0.76
[Catalytic sites of medicinal leech enzyme destabilase-lysozyme (Mldl). Structure-functional correlation]. Bioorg Khim (2012) 0.76
Increase of arterial thrombosis parameters in chronic Helicobacter pylori infection in mice. Thromb Res (2002) 0.76
[Use of the most recent reagent (CuFL) for stimulation of NO synthesis by the medicinal leech salivary cell secretion in the cultures of human endothelium cells (HUVEC) and in rat cardiomiocytes]. Biomed Khim (2012) 0.76
Fibrinogen-fibrin system regulators from bloodsuckers. Biochemistry (Mosc) (2002) 0.76
Monomerization of fragment DD by destabilase from the medicinal leech does not alter the N-terminal sequence of the gamma-chain. Thromb Res (1993) 0.76
Use of the medicinal leech in the treatment of ear diseases. ORL J Otorhinolaryngol Relat Spec (1992) 0.76
Separation of monomerizing and lysozyme activities of destabilase from medicinal leech salivary gland secretion. Biochemistry (Mosc) (2001) 0.76
Beneficial effect of ultra-low-dose aspirin in platelet activity alterations and haemorrhage observed in experimental portal hypertension. Thrombosis (2011) 0.75
Effects of external electrical stimulation on laser-beam-induced experimental thrombosis. Pathophysiol Haemost Thromb (2006) 0.75
Haemostasis defects following cardio-pulmonary by-pass based on a study of 1350 patients. Thromb Haemost (1978) 0.75
[Heart valve prosthesis and anticoagulant treatment]. Ann Cardiol Angeiol (Paris) (1993) 0.75
[Action of onion, Allium cepa L., on primary hemostasis in healthy volunteers before and after absorption of a high-fat meal]. Ann Pharm Fr (1985) 0.75
[Preventive treatments of thrombosis of aortocoronary venous bypass]. Ann Cardiol Angeiol (Paris) (1993) 0.75
Comparative study on the effects of a low molecular weight heparin (CY 216) and standard heparin in low dosage on experimental venous thrombosis. Haemostasis (1987) 0.75
[Action of prostacyclin on the extension of experimental venous thrombosis]. Ann Pharm Fr (1984) 0.75
[Hemostasis]. Rev Laryngol Otol Rhinol (Bord) (1979) 0.75
[Histologic study of venous thrombosis induced in the rat]. Ann Pharm Fr (1985) 0.75
[Are contrast agents prothrombotic?]. Ann Cardiol Angeiol (Paris) (1995) 0.75
[Low molecular weight heparins]. Ann Pharm Fr (1989) 0.75
[Role of the indirect fibrinolytic activity of heparins and similar compounds in the prevention of thrombosis]. Ann Pharm Fr (1983) 0.75
Could proteolytic enzyme modulate the interaction platelets/vessel wall in presence of ASA at ultra low doses? Thromb Res (1991) 0.75
[Variation of bleeding time after administration of acetyl salicylic acid at different doses in the healthy volunteer]. Ann Pharm Fr (1988) 0.75
Platelet aggregation on whole blood after administration of ultra low dosage acetylsalicylic acid in healthy volunteers. Thromb Res (1987) 0.75
[Difficulties of assessing postoperative pulmonary embolisms. Risks of meta-analysis from clinical trials]. Presse Med (1993) 0.75
[Oral administration of heparin and low molecular weight heparin fractions in rabbits]. Therapie (1984) 0.75
Could non steroidal anti-inflammatory drugs be used to potentiate L.M.W.H. activity in thrombosis? (Part II). Thromb Res (1992) 0.75
[Neutralization of a very low molecular weight heparin fraction CY 222 by protamine. In vitro and in vivo study]. Therapie (1987) 0.75
Thrombogenicity of ionic and nonionic contrast media tested in a laser induced rat thrombosis model. Thromb Res (1995) 0.75
[Heparin and chemically related compounds. Study in experimental thrombosis]. Ann Pharm Fr (1983) 0.75
[Passage of commercial heparin and a low molecular weight fragment of heparin, CY 222, across the placenta of pregnant rabbits]. Pathol Biol (Paris) (1985) 0.75
Prevention of laser arterial thrombus formation with unfractionated heparin. Haemostasis (1994) 0.75
Effects of polyclonal antibodies against conjugated L-dopa or against conjugated acetylcholine on experimental venous thrombosis. Thromb Res (1992) 0.75
Effects of immuno-potent drugs and their association with an unfractionated heparin on an experimental venous thrombosis. Thromb Res (1991) 0.75
The role of essential vitamins in the development of thrombosis and hemorrhage--an experimental study. Thromb Res (1992) 0.75
[Hemorheological problems and alterations in erythrocyte filterability in vascular diseases]. Acta Med Port (1983) 0.75
Are molecular weight and anti-Xa activity sufficient to predict the antithrombotic power of heparin fractions. Thromb Res (1986) 0.75
Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction. Haemostasis (1983) 0.75
[Variations in hemostasis in the infant under deep hypothermia]. Ann Anesthesiol Fr (1977) 0.75
[Artificial blood: the future of blood transfusion? I. Hemoglobin solutions]. J Pharm Belg (1990) 0.75
[Interactions between blood and biomaterials. Applications to extracorporeal circulation]. Pathol Biol (Paris) (1982) 0.75
[Artificial blood: the future of blood transfusion? II. Blood substitutes other than hemoglobin solutions]. J Pharm Belg (1990) 0.75
Comparison of the haemorrhagic effects of unfractionated heparin and a low molecular weight heparin fraction (CY 216) in rabbits. Thromb Res (1986) 0.75
[Antithrombotic agents]. Ann Cardiol Angeiol (Paris) (1993) 0.75
[Free radicals and thrombosis]. Ann Cardiol Angeiol (Paris) (1995) 0.75
[Potentiation by heparins of the action of leukocytes in experimental venous thrombosis]. Ann Pharm Fr (1988) 0.75
Is pulmonary embolism a suitable evaluation criterion of the efficacy of prophylactic treatment in surgery. Semin Thromb Hemost (1991) 0.75
[In vitro and in vivo neutralisation of a low molecular weight heparin fraction CY 216 by protamine]. Ann Pharm Fr (1986) 0.75
Effect of hirudin on the chemotactic properties of alpha-thrombin. Haemostasis (1991) 0.75
[Presence of radioactivity in the gastric juice of dogs after the intracardiac injection of 3H-or 35S-labeled heparin]. C R Seances Acad Sci III (1983) 0.75